{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:17Z","timestamp":1787020577212,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prescription opioids remain an important contributor to the United States opioid crisis and to the development of opioid use disorder for opioid-na\u00efve individuals. Recent legislative actions, such as the implementation of state prescription drug monitoring programs (PDMPs), aim to reduce opioid morbidity and mortality through enhanced tracking and reporting of prescription data. The primary objective of our study was to describe the opioid prescribing trends in the state of Pennsylvania (PA) as recorded by the PA PDMP following legislative changes in reporting guidelines, and discuss the PDMP\u2019s role in a multifactorial approach to opioid harm reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>State-level opioid prescription data summaries recorded by the PA PDMP for each calendar quarter from August 2016 through March 2020 were collected from the PA Department of Health. Data for oxycodone, hydrocodone, and morphine were analyzed by quarter for total prescription numbers and refills. Prescription lengths, pill quantities, and average morphine milliequivalents (MMEs) were analyzed by quarter for all 14 opioid prescription variants recorded by the PA PDMP. Linear regression was conducted for each group of variables to identify significant differences in prescribing trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For total prescriptions dispensed, the number of oxycodone, hydrocodone, and morphine prescriptions decreased by 34.4, 44.6, and 22.3% respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Refills fluctuated less consistently with general peaks in Q3 of 2017 and Q3 of 2018 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.2878). The rate of prescribing for all opioid prescription lengths decreased, ranging in frequency from 22 to 30\u2009days (47.5% of prescriptions) to 31+ days of opioids (0.8% of prescriptions) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Similarly, decreased prescribing was observed for all prescription amounts, ranging in frequency from 22 to 60 pills (36.6% of prescriptions) to 60\u201390 pills (14.2% of prescriptions) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Overall, the average MME per opioid prescription decreased by 18.9%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Per the PA PDMP database, opioid prescribing has decreased significantly in PA from 2016 to 2020. The PDMP database is an important tool for tracking opioid prescribing trends in PA, and PDMPs structured similarly in other states may enhance our ability to understand and influence the trajectory of the U.S. opioid crisis. Further research is needed to determine optimal PDMP policies and practices nationwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-023-09272-3","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T21:02:17Z","timestamp":1681333337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The prescription drug monitoring program in a multifactorial approach to the opioid crisis: PDMP data, Pennsylvania, 2016\u20132020"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-0012","authenticated-orcid":false,"given":"Jenna R.","family":"Adalbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Syal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif M.","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"9272_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4792","volume":"359","author":"MA Makary","year":"2017","unstructured":"Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ. 2017;359:j4792.","journal-title":"BMJ."},{"issue":"9","key":"9272_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.2106\/JBJS.19.01052","volume":"102","author":"J Schommer","year":"2020","unstructured":"Schommer J, Allen S, Scholz N, Reams M, Bohn D. Evaluation of quality improvement methods for altering opioid prescribing behavior in hand surgery. J Bone Joint Surg Am. 2020;102(9):804\u201310.","journal-title":"J Bone Joint Surg Am"},{"issue":"20","key":"9272_CR3","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.15.00614","volume":"98","author":"N Kim","year":"2016","unstructured":"Kim N, Matzon JL, Abboudi J, Jones C, Kirkpatrick W, Leinberry CF, et al. A prospective evaluation of opioid utilization after upper-extremity surgical procedures: identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am. 2016;98(20):e89.","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"9272_CR4","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.5435\/JAAOS-D-19-00030","volume":"28","author":"EY Chen","year":"2020","unstructured":"Chen EY, Betancourt L, Li L, Trucks E, Marcantonio A, Tornetta P. Standardized, patient-specific, postoperative opioid prescribing after inpatient Orthopaedic surgery. J Am Acad Orthop Surg. 2020;28(7):e304\u201318.","journal-title":"J Am Acad Orthop Surg"},{"issue":"3","key":"9272_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/0363546517693665","volume":"45","author":"K Kumar","year":"2017","unstructured":"Kumar K, Gulotta LV, Dines JS, Allen AA, Cheng J, Fields KG, et al. Unused opioid pills after outpatient shoulder surgeries given current perioperative prescribing habits. Am J Sports Med. 2017;45(3):636\u201341.","journal-title":"Am J Sports Med"},{"issue":"3","key":"9272_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMsa1406143","volume":"372","author":"RC Dart","year":"2015","unstructured":"Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"9272_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamasurg.2018.2666","volume":"153","author":"RS Stucke","year":"2018","unstructured":"Stucke RS, Kelly JL, Mathis KA, Hill MV, Barth RJ. Association of the use of a mandatory prescription drug monitoring program with prescribing practices for patients undergoing elective surgery. JAMA Surg. 2018;153(12):1105\u201310.","journal-title":"JAMA Surg"},{"key":"9272_CR8","unstructured":"Centers for Disease Control and Prevention. Drug Overdose Deaths. U.S. Department of Health and Human Services. 2021 March 3 [Cited 2021 July 5]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html."},{"key":"9272_CR9","unstructured":"UptoDate. Prescription of opioids for acute pain in opioid Na\u00efve patients. UpToDate. 2022 May 9 [Cited 2022 Sep 9]. Available from: https:\/\/www.uptodate.com\/contents\/prescription-of-opioids-for-acute-pain-in-opioid-naive-patients."},{"key":"9272_CR10","unstructured":"Centers for Disease Control and Prevention. Opioid guideline Review. U.S. Department of Health and Human Services. 2021 February 17 [Cited 2021 April 9]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/prescribing\/guideline.html."},{"issue":"4","key":"9272_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jamcollsurg.2018.07.659","volume":"227","author":"HN Overton","year":"2018","unstructured":"Overton HN, Hanna MN, Bruhn WE, Hutfless S, Bicket MC, Makary MA, et al. Opioid-prescribing guidelines for common surgical procedures: an expert panel consensus. J Am Coll Surg. 2018;227(4):411\u20138.","journal-title":"J Am Coll Surg"},{"key":"9272_CR12","unstructured":"Centers for Disease Control and Prevention. PDMPs: What States Need to Know. U.S. Department of Health and Human Services. 2021 May 19 [Cited 2021 June 9]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/pdmp\/states.html."},{"key":"9272_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2019.02.010","volume":"199","author":"GK Strickler","year":"2019","unstructured":"Strickler GK, Zhang K, Halpin JF, Bohnert ASB, Baldwin GT, Kreiner PW. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019;199:1\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"9272_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1526-4637.2012.01327.x","volume":"13","author":"LM Reifler","year":"2012","unstructured":"Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse\/misuse? Pain Med. 2012;13(3):434\u201342.","journal-title":"Pain Med"},{"issue":"1","key":"9272_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2197-1714-1-9","volume":"1","author":"G Li","year":"2014","unstructured":"Li G, Brady JE, Lang BH, Giglio J, Wunsch H, DiMaggio C. Prescription drug monitoring and drug overdose mortality. Inj Epidemiol. 2014;1(1):9.","journal-title":"Inj Epidemiol"},{"key":"9272_CR16","unstructured":"Centers for Disease Control and Prevention. Drug Overdose Mortality by State. U.S. Department of Health and Human Services. 2021 February 12 [Cited 2021 April 11]. Available from: https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm#tabs-2-2."},{"key":"9272_CR17","unstructured":"National Institute on Drug Abuse. Pennsylvania: Opioid-Involved Deaths and Related Harms. U.S. Department of Health and Human Services. 3 April 2020 [Cited 2021 April 11]. Available from: https:\/\/www.drugabuse.gov\/drug-topics\/opioids\/opioid-summaries-by-state\/pennsylvania-opioid-involved-deaths-related-harms."},{"issue":"10","key":"9272_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.15585\/mmwr.mm6610a1","volume":"66","author":"A Shah","year":"2017","unstructured":"Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1\u20132","key":"9272_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","volume":"132","author":"CM Jones","year":"2013","unstructured":"Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013;132(1\u20132):95\u2013100.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"9272_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","volume":"71","author":"TJ Cicero","year":"2014","unstructured":"Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821\u20136.","journal-title":"JAMA Psychiatry"},{"key":"9272_CR21","unstructured":"Pennsylvania Medical Society. Answers to Physician Questions on Pennsylvania's Opioid Treatment Agreement Law. 2020 March 9 [Cited 2021 April 11]. Available from: https:\/\/www.pamedsoc.org\/list\/articles\/opioid-patient-treatment-agreements"},{"key":"9272_CR22","unstructured":"2014 Act 191 - PA General Assembly [Internet]. [cited 2021 Apr 10]. Available from: https:\/\/www.legis.state.pa.us\/cfdocs\/legis\/li\/uconsCheck.cfm?yr=2014&sessInd=0&act=191."},{"key":"9272_CR23","unstructured":"Coelho J. Changes to Pennsylvania Drug Monitoring Program as of January 1, 2017: Compliance for Prescribing Physicians. McNees Wallace & Nurick LLC. 2017 January 16 [Cited 2021 April 8]. Available from: https:\/\/www.mcneeslaw.com\/changes-pennsylvania-drug-monitoring-program-january-1-2017-compliance-prescribing-physicians\/."},{"key":"9272_CR24","unstructured":"Drug Enforcement Agency, University of Pittsburgh. The Opioid Threat in Pennsylvania. 2018 September [Cited 2021 April 8]. Available from: https:\/\/www.dea.gov\/sites\/default\/files\/2018-10\/PA%20Opioid%20Report%20Final%20FINAL.pdf."},{"key":"9272_CR25","unstructured":"United states census bureau. Census Data 2022. [Cited 2022 September 10]. Available from: https:\/\/data.census.gov\/cedsci\/."},{"key":"9272_CR26","unstructured":"Centers for Disease Control and Prevention. U.S. Opioid Dispensing Rate Maps. U.S. Department of Health and Human Services. 2021 November [Cited 2022 September 9]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html."},{"key":"9272_CR27","unstructured":"Harvard Health Publishing. Is tramadol a risky pain medication? Harvard University. 2019 June [Cited 2022 September 10]. Available from: https:\/\/www.health.harvard.edu\/blog\/is-tramadol-a-risky-pain-medication-2019061416844."},{"issue":"10","key":"9272_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.2019.1347","volume":"321","author":"C Zeng","year":"2019","unstructured":"Zeng C, Dubreuil M, LaRochelle MR, Lu N, Wei J, Choi HK, et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA. 2019;321(10):969\u201382.","journal-title":"JAMA."},{"key":"9272_CR29","unstructured":"U.S. Department of Health and Human Services. Biden Administration Announces $1.5 Billion Funding Opportunity for State Opioid Response Grant Program. U.S. Department of Health and Human Services. 2022 May [Cited 2022 September 25]. Available from: https:\/\/www.hhs.gov\/about\/news\/2022\/05\/19\/biden-administration-announces-15-billion-funding-opportunity-state-opioid-response-grant-program.html."},{"issue":"2","key":"9272_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/1073110518782946","volume":"46","author":"AM Parker","year":"2018","unstructured":"Parker AM, Strunk D, Fiellin DA. State responses to the opioid crisis. J Law Med Ethics. 2018;46(2):367\u201381.","journal-title":"J Law Med Ethics"},{"key":"9272_CR31","unstructured":"Pennsylvania General Assembly. Bill Information - Senate Bill 1367; Regular Session 2015-2016. 2016 [Cited 2021 Apr 21]. Available from: https:\/\/www.legis.state.pa.us\/CFDOCS\/billInfo\/billInfo.cfm?syear=2015&sInd=0&body=S&type=B&bn=1367."},{"key":"9272_CR32","unstructured":"Pennsylvania General Assembly. Bill Information - House Bill 1699; Regular Session 2015-2016. 2016 [Cited 2021 Apr 21]. Available from: https:\/\/www.legis.state.pa.us\/cfdocs\/billInfo\/billInfo.cfm?sYear=2015&sInd=0&body=H&type=B&bn=1699."},{"key":"9272_CR33","unstructured":"Pennsylvania General Assembly. 2016 Act 124. 2016 [Cited 2021 April 21]. Available from: https:\/\/www.legis.state.pa.us\/cfdocs\/legis\/li\/uconsCheck.cfm?yr=2016&sessInd=0&act=124."},{"issue":"4","key":"9272_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","volume":"49","author":"CM Jones","year":"2015","unstructured":"Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49(4):493\u2013501.","journal-title":"Am J Prev Med"},{"issue":"11\u201312","key":"9272_CR35","first-page":"42","volume":"9","author":"RA Sansone","year":"2012","unstructured":"Sansone RA, Sansone LA. Doctor shopping: a phenomenon of many themes. Innov Clin Neurosci. 2012;9(11\u201312):42\u20136.","journal-title":"Innov Clin Neurosci"},{"issue":"6","key":"9272_CR36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1377\/hlthaff.2015.1673","volume":"35","author":"Y Bao","year":"2016","unstructured":"Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HA, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35(6):1045\u201351.","journal-title":"Health Aff (Millwood)."},{"issue":"4","key":"9272_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1377\/hlthaff.2016.1141","volume":"36","author":"H Wen","year":"2017","unstructured":"Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to medicaid enrollees. Health Aff (Millwood). 2017;36(4):733\u201341.","journal-title":"Health Aff (Millwood)."},{"issue":"10","key":"9272_CR38","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1377\/hlthaff.2016.0448","volume":"35","author":"D Dowell","year":"2016","unstructured":"Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff (Millwood). 2016;35(10):1876\u201383.","journal-title":"Health Aff (Millwood)."},{"issue":"8","key":"9272_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135957","volume":"10","author":"L Rasubala","year":"2015","unstructured":"Rasubala L, Pernapati L, Velasquez X, Burk J, Ren Y-F. Impact of a mandatory prescription drug monitoring program on prescription of opioid analgesics by dentists. PLoS One. 2015;10(8):e0135957.","journal-title":"PLoS One"},{"key":"9272_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.drugalcdep.2018.03.036","volume":"188","author":"EL Winstanley","year":"2018","unstructured":"Winstanley EL, Zhang Y, Mashni R, Schnee S, Penm J, Boone J, et al. Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug Alcohol Depend. 2018;188:169\u201374.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"9272_CR41","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1377\/hlthaff.2017.1321","volume":"37","author":"RL Haffajee","year":"2018","unstructured":"Haffajee RL, Mello MM, Zhang F, Zaslavsky AM, Larochelle MR, Wharam JF. Four states with robust prescription drug monitoring programs reduced opioid dosages. Health Aff (Millwood). 2018;37(6):964\u201374.","journal-title":"Health Aff (Millwood)."},{"key":"9272_CR42","unstructured":"Death Data Overview \u2013 OverdoseFreePA [Internet]. [cited 2021 Jun 12]. Available from: https:\/\/www.overdosefreepa.pitt.edu\/know-the-facts\/death-data-overview\/."},{"issue":"5","key":"9272_CR43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1526-4637.2011.01062.x","volume":"12","author":"LJ Paulozzi","year":"2011","unstructured":"Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747\u201354.","journal-title":"Pain Med"},{"issue":"1","key":"9272_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/epirev\/mxaa002","volume":"42","author":"V Puac-Polanco","year":"2020","unstructured":"Puac-Polanco V, Chihuri S, Fink DS, Cerd\u00e1 M, Keyes KM, Li G. Prescription drug monitoring programs and prescription opioid-related outcomes in the United States. Epidemiol Rev. 2020;42(1):134\u201353.","journal-title":"Epidemiol Rev"},{"issue":"6","key":"9272_CR45","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.sapharm.2016.12.002","volume":"13","author":"NA Carnes","year":"2017","unstructured":"Carnes NA, Wright ER, Norwood CW. A qualitative analysis of prescribers\u2019 and dispensers\u2019 views on improving prescription drug monitoring programs. Res Social Adm Pharm. 2017;13(6):1167\u201374.","journal-title":"Res Social Adm Pharm"},{"issue":"4","key":"9272_CR46","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/acem.12905","volume":"23","author":"SJ Poon","year":"2016","unstructured":"Poon SJ, Greenwood-Ericksen MB, Gish RE, Neri PM, Takhar SS, Weiner SG, et al. Usability of the Massachusetts prescription drug monitoring program in the emergency department: a mixed-methods study. Acad Emerg Med. 2016;23(4):406\u201314.","journal-title":"Acad Emerg Med"},{"issue":"3","key":"9272_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1377\/hlthaff.2014.1085","volume":"34","author":"L Rutkow","year":"2015","unstructured":"Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff (Millwood). 2015;34(3):484\u201392.","journal-title":"Health Aff (Millwood)"},{"key":"9272_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jsat.2016.07.013","volume":"70","author":"CJ Blum","year":"2016","unstructured":"Blum CJ, Nelson LS, Hoffman RS. A survey of physicians\u2019 perspectives on the New York state mandatory prescription monitoring program (ISTOP). J Subst Abus Treat. 2016;70:35\u201343.","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"9272_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11420-018-9633-5","volume":"15","author":"D Leas","year":"2019","unstructured":"Leas D, Seymour RB, Wally MK, Hsu JR, PRIMUM Group. Use of a prescription drug-monitoring program by emergency and surgical prescribers: results of a hospital survey. HSS J. 2019;15(1):51\u20136.","journal-title":"HSS J"},{"key":"9272_CR50","unstructured":"Substance Use Philadelphia. Sales and prescribing - sales of controlled substances. Philadelphia department of Public Health 2020 [Cited 2021 June 12]. Available from: https:\/\/www.substanceusephilly.com\/sales-controlled-substances."},{"key":"9272_CR51","unstructured":"Centers for Disease Control and Prevention. Drug Overdose - State Successes. U.S. Department of Health and Human Services. 2019 July 29 [Cited 2021 June 12]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/policy\/successes.html."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09272-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-09272-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-09272-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T21:03:28Z","timestamp":1681333408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-09272-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["9272"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-09272-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Per the Thomas Jefferson University Institutional Review Board, this population-level data analysis project did not constitute human subjects research and was granted approval without review or exemption. All study methods were performed in accordance with the Federal Wide Assurance guidelines of the U.S. Department of Health and Human Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or non-financial competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"364"}}